Truscreen Group (ASX:TRU) Cyclically Adjusted Revenue per Share: A$0.01 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Truscreen Group Cyclically Adjusted Revenue per Share?

Truscreen Group ASX:TRU +7.69% Cyclically Adjusted Revenue per Share is A$0.01 as of Mar. 2026. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Truscreen Group's adjusted revenue per share data for the fiscal year that ended in Mar. 2026 was A$0.003. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is A$0.01 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-19), Truscreen Group's current stock price is A$ 0.014. Truscreen Group's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Mar. 2026 was A$0.01. Truscreen Group's Cyclically Adjusted PS Ratio of today is 1.40.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Truscreen Group was 3.18. The lowest was 1.50. And the median was 1.80.


Truscreen Group  (ASX:TRU) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Truscreen Group's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.014/0.01
=1.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Truscreen Group was 3.18. The lowest was 1.50. And the median was 1.80.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Truscreen Group Cyclically Adjusted Revenue per Share Related Terms


Truscreen Group Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Truscreen Group's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Truscreen Group Cyclically Adjusted Revenue per Share Chart

Truscreen Group Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.01 0.00 0.01

Truscreen Group Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.01 0.00 0.00 0.01

ASX:TRU vs ABT, SYK, MDT: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Truscreen Group's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Truscreen Group Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Truscreen Group's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Truscreen Group's Cyclically Adjusted PS Ratio falls into.



Truscreen Group Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Truscreen Group's adjusted Revenue per Share data for the fiscal year that ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.003/136.8867*136.8867
=0.003

Current CPI (Mar. 2026) = 136.8867.

Truscreen Group Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201703 0.003 102.231 0.004
201803 0.004 103.355 0.005
201903 0.008 104.889 0.010
202003 0.005 107.547 0.006
202103 0.003 109.182 0.004
202203 0.004 116.747 0.005
202303 0.004 124.517 0.004
202403 0.004 129.526 0.004
202503 0.003 132.798 0.003
202603 0.003 136.887 0.003

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of A$0.01 mean?
Truscreen Group (ASX:TRU) has a Cyclically Adjusted Revenue per Share of A$0.01 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Truscreen Group and its competitors.
Is Truscreen Group's Cyclically Adjusted Revenue per Share too high?
Truscreen Group's current Cyclically Adjusted Revenue per Share is A$0.01.
How does Truscreen Group's Cyclically Adjusted Revenue per Share compare to ABT and SYK?
Truscreen Group's Cyclically Adjusted Revenue per Share of A$0.01 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Truscreen Group and its competitors. Truscreen Group's current Cyclically Adjusted Revenue per Share is A$0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Truscreen Group stock overvalued right now?
Based on GuruFocus' analysis, Truscreen Group (ASX:TRU) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.01 — trading 30% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is A$0.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Truscreen Group (ASX:TRU), the current Cyclically Adjusted Revenue per Share is A$0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Truscreen Group Business Description

Other Exchanges TRU:New Zealand
Address C/- HLB Mann Judd Limited, 57 Symonds Street, Level 6, Equitable House, Grafton, Auckland, NZL, 1010
Truscreen Group Ltd is a medical device company. The company manufactures and distributes the Truscreen Cervical Cancer screening device, which comprises a medical device and process designed to detect the presence in real-time of precancerous and cancerous tissue on the cervix. The product utilizes technology to detect the pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurements of cervical tissue. Geographically, the company operates its business in New Zealand, Mexico, China, Russia, Zimbabwe, Vietnam, and other countries. Maximum revenue is generated from China.